Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 17.76 percent. This is a 19.35 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $8.153 million which beat the analyst consensus estimate of $6.197 million by 31.57 percent. This is a 4.42 percent increase over sales of $7.808 million the same period last year.